View article

Background:

Hyperuricemia is associated with elevated risks of cardiovascular and chronic kidney disease (CKD). Since inhibition of urate transporter 1 has been suggested to be potentially nephroprotective, we performed a phase 2b study to assess albuminuria lowering effects of the urate transporter 1 inhibitor verinurad combined with the xanthine oxidase inhibitor allopurinol in patients with CKD and hyperuricemia.

Methods:

In this randomized placebo and active controlled trial, we enrolled participants with serum urate concentrations≥ 6.0 mg/dL, estimated glomerular filtration rate (eGFR)≥ 25 mL/minute/1.73 m 2 and a urinary albumin-to-creatinine ratio (UACR) 30-5000 mg/g to one of five treatment arms: placebo, placebo+ allopurinol 300 mg/day, verinurad 3 mg+ allopurinol 300 mg/day, verinurad 7.5 mg+ allopurinol 300 mg/day or verinurad 12 mg+ allopurinol 300 mg/day in a 1: 1: 1: 1: 1 ratio. The primary …